Status:
RECRUITING
Predictive Biomarkers for Pneumonitis After Chemoradiotherapy and Immunotherapy in Patients With Non-small Cell Lung Cancer
Lead Sponsor:
M.D. Anderson Cancer Center
Conditions:
Lung Non-Small Cell Carcinoma
Eligibility:
All Genders
Brief Summary
This study looks at the side effects of chemotherapy and radiation (chemoradiation) followed by immunotherapy in patients with non-small cell lung cancer, with a particular focus on lung inflammation ...
Detailed Description
PRIMARY OBJECTIVE: I. To assess the association between the incidence of concurrent chemoradiation and subsequent immunotherapy-related adverse events, particularly radiation and immune-related pneum...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Newly-diagnosed NSCLC patients who will be undergoing concurrent chemotherapy and radiotherapy (XRT) followed by immune checkpoint inhibitors (CPI) therapy with durvalumab, as per the PACIFIC trial
- Willing to undergo all treatment and evaluation at MD Anderson Cancer Center (MDACC)
- Has access to a smartphone with the ability to transmit data via wireless connection or through their personal cellular plan
- Able and willing to perform home spirometry (HS) weekly without absolute contraindications to performing spirometry
Exclusion
Key Trial Info
Start Date :
January 21 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 2 2027
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT04913311
Start Date
January 21 2021
End Date
February 2 2027
Last Update
August 14 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
M D Anderson Cancer Center
Houston, Texas, United States, 77030